Eli Lilly Stock Jumps Higher After Analyst Upgrade

Shares moved further into overbought territory

Eli Lilly and Company (LLY) shares rose more than 3% during Wednesday's session after Morgan Stanley upgraded the stock from Equal Weight to Overweight and raised its price target from $116 to $150 per share. Analyst David Risinger cited strong earnings growth potential and significant pipeline optionality from its small size and low margins. Given Eli Lilly's strong R&D leadership, Risinger believes that the market underappreciates the company's long-term growth prospects.

In separate news, the company announced the start of a long-term study, TRIUMPH, evaluating the effectiveness of Emgality (galcanezumab-gnlm) compared to other preventative treatments for migraine among people switching from a different treatment or starting a new prescription treatment. The 2,850-subject trial will track prescriptions and treatment choices among migraine sufferers over a two-year time frame. Emgality generated $47.7 million in worldwide revenue during Q3 2019.

Chart showing the share price performance of Eli Lilly and Company (LLY)

From a technical standpoint, Eli Lilly stock broke out sharply higher to test its highs made earlier this year. The relative strength index (RSI) moved further into overbought territory with a reading of 86.63, but the moving average convergence divergence (MACD) remains in a bullish uptrend. The stock could also experience a near-term golden cross – or a bullish crossover of its 50- and 200-day moving averages. These indicators suggest that the stock could see some near-term consolidation before extending its move higher over the coming sessions.

Traders should watch for some consolidation near its prior highs of around $130 over the coming sessions. If the stock breaks out, traders could see a move to fresh 52-week highs. If the stock breaks down lower, traders could see a move toward R2 resistance at $123.81 or trendline support near $120. The bullish technical and fundamental backdrop suggest that the intermediate-term trend will remain higher.

The author holds no position in the stock(s) mentioned except through passively managed index funds.

Take the Next Step to Invest
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.